MedTrace Logo

Clinical Outcomes of MICROPURE and PodEye Monofocal Intraocular Lenses

NCT03796624 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2021-07-09

No results posted yet for this study

Summary

Prospective, non-randomised, open, controlled, single-center post-market clinical follow study about Micropure 1.2.3. and PODEYE intraocular lenses.

Conditions

  • Cataract
  • Lens Opacities

Interventions

DEVICE

Micropure 1.2.3.

Implantation of intraocular lens (IOL). Name: "MicroPure 1.2.3." It is a monofocal intraocular lens consisting of hydrophobic acrylic material. One IOL per patient will be implanted

DEVICE

PODEYE

Implantation of intraocular lens (IOL). Name: "PODEYE" It is a monofocal intraocular lens consisting of hydrophobic acrylic material. The IOL will be implanted in the contralateral eye of the same patient already implanted with Micropure 1.2.3.

Sponsors & Collaborators

  • Beaver-Visitec International, Inc.

    lead INDUSTRY

Principal Investigators

  • Pavel Stodůlka, MD, PhD · Gemini Eye Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-12
Primary Completion
2021-06-17
Completion
2021-06-17

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03796624 on ClinicalTrials.gov